| PHAT Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the PHAT shares outstanding history going back to 10/25/2019:
Also see: PHAT Market Cap History PHAT YTD Return |
PHAT Shares Outstanding History — Phathom Pharmaceuticals Share Count Over Time
As of 4/28/2026 Phathom Pharmaceuticals has 79.76 million PHAT shares outstanding. Investors often track the PHAT shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows PHAT share count trends over time, with 28 historical shares outstanding datapoints presented, dating back to 10/25/2019.
| PHAT Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PHAT Historical Shares Outstanding: +18.86% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PHAT Stock Price Chart |
| About Phathom Pharmaceuticals Inc |
| Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. Co.'s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. We show 28 historical shares outstanding datapoints in our coverage of PHAT's shares outstanding history. Understanding the changing numbers of PHAT shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like PHAT versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching PHAT by allowing them to research PHAT shares outstanding history as well as any other stock in our coverage universe. |
| PHAT Current Stock Quote |
Quotes delayed 20 minutes  Free PHAT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| PHAT Share Performance |
| Shares Outstanding Peers |
| Phathom Pharmaceuticals (PHAT) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
PHIO Shares Outstanding History PIII Shares Outstanding History PIRS Shares Outstanding History PKI Shares Outstanding History PLRX Shares Outstanding History PLSE Shares Outstanding History PLUR Shares Outstanding History PLXP Shares Outstanding History PMCB Shares Outstanding History PMD Shares Outstanding History More Healthcare companies » |
PHAT Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
